Compare PIPR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIPR | PCVX |
|---|---|---|
| Founded | 1895 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 8.7B |
| IPO Year | 2003 | 2020 |
| Metric | PIPR | PCVX |
|---|---|---|
| Price | $88.53 | $60.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $91.38 | $88.25 |
| AVG Volume (30 Days) | 468.8K | ★ 1.1M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 54.49 | N/A |
| EPS | ★ 15.82 | N/A |
| Revenue | ★ $1,904,217,000.00 | N/A |
| Revenue This Year | $12.30 | N/A |
| Revenue Next Year | $13.55 | N/A |
| P/E Ratio | $5.52 | ★ N/A |
| Revenue Growth | ★ 24.33 | N/A |
| 52 Week Low | $72.48 | $28.09 |
| 52 Week High | $380.26 | $65.00 |
| Indicator | PIPR | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 20.05 | 56.97 |
| Support Level | $72.48 | $42.30 |
| Resistance Level | $341.25 | $65.00 |
| Average True Range (ATR) | 2.64 | 2.30 |
| MACD | 5.80 | 0.46 |
| Stochastic Oscillator | 96.88 | 74.55 |
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.